There are numerous Research opportunities for Medicine residents to engage in at Augusta University. In addition to the research track, residents can opt to participate in a variety of research projects which may include basic, clinical, and translational investigation.
MCG Department of Medicine Research
| Medicine Departments within 10 positions of DoM | ||
| University of Nebraska | 57 | $18.5 |
| Rush Medical Center | 58 | $17.3 |
| University of UConn | 59 | $16.8 |
| University of Louisville | 60 | $16.2 |
| University of Cincinnati | 61 | $15.5 |
| Augusta University | 62 | $13.5 |
| Penn State | 63 | $13.2 |
| University of New Mexico | 64 | $12.4 |
| University of Kentucky | 65 | $11.6 |
| University of Hawaii | 66 | $11.5 |
| VCU | 67 | $11.3 |
TheTranslational Research Program of the Departmentoffers support for mentor identification, project design, ancillary support (study coordinators and statistics), and research funding. Many residents use this pathway for getting involved in a meaningful project, but it is by no means the only option. Individual faculty are always amenable to working with motivated residents and also provide a rewarding research experience.
2023-2024
Standridge M, et al. 2023. Therapy related multiple myeloma: A distinct entity.Blood,142 (supplement 1): 6657.https://doi.org/10.1182/blood-2023-190298
Standridge M, et al. 2023. Prephase Cyclophosphamide: A advantage bridge to definitive therapy.Blood, 142 (supplement 1): 6316.http://doi.org/10.1182/blood-2023-190805
Desai S, Standridge M, et al. 2023. Eliminating racial disparities among transplant patients in multiple myeloma after referral to a tertiary center.Blood, 142 (supplement 1): 6659.http://doi.org/10.1182/blood-2023-190828
Matosz S, Standridge M, et al. 2023. Outcomes in acute lymphoid leukemia patients with incomplete hyper-CVAD cycles.Blood, 142 (supplement 1): 5887.http://doi.org/10.1182/blood-2023-190334
Dickey J, Standridge M et al. 2023. The overuse of C. difficile testing among autologous transplant patients with melphalan conditioning: a single center experience.Blood, 142 (supplement 1): 7065.http://doi.org/10.1182/blood-2023-191226
Standridge M, Desai S, Yerraguntla S, Bradshaw D, Mian M, Shah A, Kota V, Jillela A, Cortex J, Chauhan A, Kerakous A, and Bryan L. 2023. “Prephase Cyclophosphamide: A advantage bridge to definitive therapy.”
